Research

Global consortium to study Pick’s disease, rare form of early-onset dementia
April 27, 2024
JACKSONVILLE, Fla. — Pick's disease, a neurodegenerative disease of unknown genetic origin, is a rare type of frontotemporal dementia that affects people under the age of 65. The condition causes changes in personality, behavior and sometimes language impairment. In patients with the disease,...
Read More
Mayo Clinic Minute: Treatment and research of glioblastoma
April 25, 2024
Considered the most aggressive type of brain cancer, glioblastoma grows rapidly, destroying healthy tissue. Globally, approximately 300,000 people are diagnosed each year with glioblastoma. Watch: The Mayo Clinic Minute https://youtu.be/DP7p09z_mOY Journalists: Broadcast-quality video (1:05) is...
Read More
More than 90 articles from 25 countries featured in Mayo Clinic Proceedings: Digital Health journal’s first year
April 13, 2024
Mayo Clinic Proceedings: Digital Health, an open-access companion journal to the widely read and cited Mayo Clinic Proceedings, is marking its first anniversary, having published more than 90 articles on the digital transformation of healthcare internationally. Authors published in Mayo Clinic ...
Read More
Mayo Clinic study finds active workstations may improve cognitive performance
April 7, 2024
ROCHESTER, Minn. — A recent Mayo Clinic study suggests that active workstations incorporating a walking pad, bike, stepper and/or standing desk are successful strategies for reducing sedentary time and improving mental cognition at work without reducing job performance. Extended sedentary beh...
Read More
New heated drug baths provide hope for patients with stomach cancer
April 7, 2024
Mayo Clinic researchers used a new approach to chemotherapy to more than double the typical survival rate for patients with stomach cancer and peritoneal metastasis, which is cancer that has spread to the lining of the abdominal cavity.Powered by ...
Read More
New study finds triple-negative breast cancer tumors with an increase in immune cells have lower risk of recurrence after surgery
April 5, 2024
ROCHESTER, Minn. — A new multicenter, international study suggests that people who have early-stage triple-negative breast cancer (TNBC) and high levels of immune cells within their tumors may have a lower risk of recurrence and better survival rates even when not treated with chemotherapy. T...
Read More
Could CAR-T cell therapy improve kidney transplants?
April 5, 2024
Chimeric antigen receptor-T cell therapy (CAR-T cell therapy) could provide a revolutionary approach to organ transplantation for patients who are hard to match and susceptible to rejection, Mayo Clinic researchers discovered. Their pioneering research focuses on using CAR-T cells derived from ...
Read More
Mayo Clinic, Terasaki Institute launch collaboration for transplant innovation
April 4, 2024
JACKSONVILLE, Fla. — Mayo Clinic and Terasaki Institute for Biomedical Innovation announced today a research collaboration centered on improving organ transplant outcomes. Beginning in April, Mayo Clinic biomedical researchers and Terasaki Institute scientists will work together on two core a...
Read More
Study documents safety, improvements from stem cell therapy after spinal cord injury
April 4, 2024
ROCHESTER, Minn. — A Mayo Clinic study shows stem cells derived from patients' own fat are safe and may improve sensation and movement after traumatic spinal cord injuries. The findings from the phase 1 clinical trial appear in Nature Communications. The results of this early research offer i...
Read More
Social isolation linked to biological age gap, higher mortality rate
April 4, 2024
Mayo Clinic research finds a connection between Social Network Index score and AI-determined biological age ROCHESTER, Minn. — A new study from Mayo Clinic finds that socially isolated people are more likely to show signs of being biologically older than their age and more likely to die from ...
Read More
Psilocybe cubensis extract potently prevents fear memory recall and freezing behavior in short- but not long-term in a rat model of posttraumatic stress disorder.
Psilocybe cubensis is a species of psilocybin mushroom (magic mushroom) of moderate potency whose principal active compounds are psilocybin and psilocin. Recent studies have shown the significant procognitive and mood-enhancer effects of Psilocybe cubensis. However, evidence is so limited, especially in preclinical studies. We aimed to investigate the effect of Psilocybe cubensis extract on posttraumatic stress disorder (PTSD)-like behavior, pain perception, locomotor activity, and anxiety in a rat model of PTSD. Male rats were exposed to three consecutive shocks (0.8 mA, 3 s interval) paired with three sounds broadcasted 3 s before delivering shocks (75 dB, 3 s). After 1, 3, or 21 days, fre...
Read Article
Sex similarities and dopaminergic differences in interval timing.
Rodent behavioral studies have largely focused on male animals, which has limited the generalizability and conclusions of neuroscience research. Working with humans and rodents, we studied sex effects during interval timing that requires participants to estimate an interval of several seconds by making motor responses. Interval timing requires attention to the passage of time and working memory for temporal rules. We found no differences between human females and males in interval timing response times (timing accuracy) or the coefficient of variance of response times (timing precision). Consistent with prior work, we also found no differences between female and male rodents in timing accura...
Read Article
Less is more: Smaller hippocampal subfield volumes predict greater improvements in posttraumatic stress disorder symptoms over 2 years.
Posttraumatic stress disorder (PTSD) is a heterogeneous disorder, and symptom severity varies over time. Neurobiological factors that predict PTSD symptoms and their chronicity remain unclear. This study investigated whether the volume of the hippocampus and its subfields, particularly cornu ammonis (CA) 1, CA3, and dentate gyrus, are associated with current PTSD symptoms and whether they predict PTSD symptom changes over 2 years. We examined clinical and structural magnetic resonance imaging measures from 252 trauma-exposed post-9/11 veterans (159 with Time 1 PTSD diagnosis) during assessments approximately 2 years apart. Automated hippocampal subfield segmentation was performed with FreeSu...
Read Article
Indirect and direct cannabinoid agonists differentially affect mesolimbic dopamine release and related behaviors.
The cannabinoid system is being researched as a potential pharmaceutical target for a multitude of disorders. The present study examined the effect of indirect and direct cannabinoid agonists on mesolimbic dopamine release and related behaviors in C57BL/6J (B6) mice. The indirect cannabinoid agonist N-arachidonoyl serotonin (AA-5-HT) indirectly agonizes the cannabinoid system by preventing the metabolism of endocannabinoids through fatty acid amide hydrolase inhibition while also inhibiting transient receptor potential vanilloid Type 1 channels. Effects of AA-5-HT were compared with the direct cannabinoid receptor Type 1 agonist arachidonoyl-2′-chloroethylamide (ACEA). In Experiment 1, mic...
Read Article
Lrp8 knockout mice fed a selenium-replete diet display subtle deficits in their spatial learning and memory function.
Selenium is an essential trace element that is delivered to the brain by the selenium transport protein selenoprotein P (SEPP1), primarily by binding to its receptor low-density lipoprotein receptor-related protein 8 (LRP8), also known as apolipoprotein E receptor 2 (ApoER2), at the blood–brain barrier. Selenium transport is required for several important brain functions, with transgenic deletion of either Sepp1 or Lrp8 resulting in severe neurological dysfunction and death in mice fed a selenium-deficient diet. Previous studies have reported that although feeding a standard chow diet can prevent these severe deficits, some motor coordination and cognitive dysfunction rem...
Read Article